Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept.

Abstract

Over the last several years, a new generation of therapies for psoriasis has been in development. These biologic therapies target the activity of T lymphocytes and cytokines responsible for the inflammatory nature of this disease. In this review, we present an update on the progress of the four biologic agents in the forefront: infliximab, etanercept, efalizumab, and alefacept. The mechanism of each drug will be reviewed, as well as the most recent efficacy and safety data.

• Authors: Jeffrey M Weinberg, Ritu Saini, William D Tutrone
• Journal: Journal of drugs in dermatology : JDD (J Drugs Dermatol) Vol. 1 Issue 3 Pg. 303-10 (Dec 2002) ISSN: 1545-9616 [Print] United States
• PMID: 12851990 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Antirheumatic Agents
• Dermatologic Agents
• Immunoglobulin G
• Receptors, Tumor Necrosis Factor
• Recombinant Fusion Proteins
• Infliximab
• Alefacept
• Etanercept
• efalizumab

Topics

• Alefacept
• Animals
• Antibodies, Monoclonal (adverse effects, therapeutic use)
• Antibodies, Monoclonal, Humanized
• Antirheumatic Agents (adverse effects, therapeutic use)
• Biological Therapy
• Dermatologic Agents (adverse effects, metabolism, therapeutic use)
• Etanercept
• Humans
• Immunoglobulin G (adverse effects, therapeutic use)
• Infliximab
• Mice
• Psoriasis (drug therapy)
• Randomized Controlled Trials as Topic
• Receptors, Tumor Necrosis Factor (therapeutic use)
• Recombinant Fusion Proteins (adverse effects, therapeutic use)
• Treatment Outcome